Brought to you by 
Eisai gets cancer compound rights from HUYA
02 Feb 2016
Executive Summary
Eisai Co. Ltd. licensed exclusive rights from HUYA Bioscience International LLC to develop and sell the HDAC inhibitor HBI8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, the Philippines, Vietnam, and Singapore.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eisai gets cancer compound rights from HUYA
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice